Reuters logo
BRIEF-Fda staff says results supporting effect of Puma Biotechnology's neratinib
May 22, 2017 / 2:15 PM / 6 months ago

BRIEF-Fda staff says results supporting effect of Puma Biotechnology's neratinib

May 22 (Reuters) - Fda Staff -

* Based On Sensitivity Analyses Conducted, Results Appear To Be Generally Similar To Primary Analysis Results, Supporting Effect Of Puma Biotechnology Inc’s Neratinib

* Tolerability of neratinib in patient population is a concern given frequent dose interruptions, reductions, and discontinuations observed, mostly due to diarrhea

* Results from ongoing phase 2 study 6201 for neratinib suggest that antidiarrheal prophylaxis decreases the incidence and severity of diarrhea Source text (bit.ly/2rtvRyY) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below